The cardiovascular diagnostics market is valued at USD 6.5 billion in 2025. According to FMI's analysis, the industry is expected to grow at a CAGR of 5.1% and reach USD 10.69 billion by 2035.
In 2024, the global cardiovascular diagnostics and cardiac testing industry experienced significant growth due to advancements in non-invasive testing technologies, particularly in echocardiography and cardiac MRI.
Extensive deployment of AI-assisted imaging within North America and Western Europe played a giant role in diagnostic accuracy, which consequently resulted in hastened intervention procedures.
FMI analysis showed that increased payments in Japan and Germany also helped hospitals and clinics use more advanced heart tests. Private sector R&D partnerships flourished, especially in wearable cardiac monitoring technology that tracks arrhythmias and indicators of early heart failure.
Regulatory agencies also cleared several next-generation biomarkers, which improved the accuracy of ischemia and myocardial infarction diagnosis.
Stepping into 2025, FMI considers the industry poised for stable growth, as the growth will be driven by the increasing global burden of cardiac diseases, increased investment in AI-powered diagnostic systems, and dissemination of tele-cardiology platforms.
The developing economies are expected to advance their diagnostic infrastructures, and the developed economies will further evolve early detection mechanisms. Over the next decade, FMI research demonstrated that precision medicine will continue to overlap with cardiac testing to form personalised screening channels.
By 2035, the field is expected to evolve into a patient-centred, data-driven paradigm focusing on early risk stratification and less invasive treatments.
Industry Forecast Table
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 6.5 Billion |
| Industry Value (2035F) | USD 10.69 Billion |
| CAGR (2025 to 2035) | 5.1% |
The cardiovascular diagnostic industry is in a steady growth trajectory, supported by rising worldwide incidence of cardiovascular disease and more rapid uptake of AI-driven diagnostic technologies.
FMI analysis found that new technologies for detecting diseases early and less invasive tests are changing how doctors work, speeding up treatment and leading to better results.
Companies investing in digital diagnostics, telecardiology, and precision imaging are likely to gain significantly, while incumbent companies lagging in innovation may lose industry share.
Step up AI integration in diagnostics
Executives will need to invest in AI-driven imaging systems and automated ECG interpretation to improve the speed and accuracy of diagnoses, especially in busy clinical settings.
Endorse offers to align with preventive cardiology trends
FMI thinks that aligning product pipelines to match the world's transition to preventive care-i.e., remote patient monitoring, more forward biomarkers for screening diseases, and diagnostics at home-will be integral to keeping a company industry relevant.
Build strategic partnerships through the care continuum
Firms must build stronger R&D alliances and distribution channels with telehealth companies, wearable tech vendors, and hospitals to support widespread deployment and a diversified long-term pipeline.
| Risk | Probability-Impact |
|---|---|
| Regulatory Delays in AI Tool Approvals | Medium-High |
| Data Privacy Concerns in Remote Monitoring Platforms | High-Medium |
| Supply Chain Disruptions for Diagnostic Equipment Components | Medium-High |
| Priority | Immediate Action |
|---|---|
| AI-Driven Cardiac Imaging | Run feasibility on integrating machine learning algorithms in diagnostic suites |
| Remote Patient Monitoring | Initiate OEM feedback loop on wearable sensor integration and data interoperability |
| Global Distribution Expansion | Launch after industry channel partner incentive pilot in high-growth APAC and LATAM regions |
To stay ahead, companies need to reorient the cardiac testing strategy to scalable, AI-enabled platforms and proactive patient engagement models. This type of intelligence marks a shift from one-time tests to ongoing, preventive monitoring, which requires initial spending on remote devices, efforts to get AI approved by regulators, and partnerships with tech-focused manufacturers.
FMI analysis concluded that organisations adopting this transformation will achieve clinical mindshare and realise recurring revenue streams through service-based diagnostic ecosystems. The coming 12 months must prioritise aligning capital investment with the long-term digital transformation of healthcare.
Regional Insights
Diverging Perceptions of Return on Investment (ROI)
Cloud-Enabled Systems
Chosen by 66% across the world due to flexibility in decentralised care models.
Manufacturers
Future Investment Priorities
High Consensus: Geography-extended stakeholders converge on diagnostic reliability, AI integration, and cost savings as factors that will decide next-generation competitiveness.
Divergences of note
Strategic Insights: Companies will have to devise product portfolios-focusing on AI and velocity in the USA, regulatory strength and green tech in Europe, and lightweight, price-sensitive innovation in Asia-to realise maximum growth potential.
| Countries | Regulatory Impact & Mandatory Certifications |
|---|---|
| United States | FDA regulation via 510(k) or PMA is required for cardiovascular diagnostic devices. The FDA Digital Health Software Precertification Program is streamlining AI-based tool clearance, albeit data privacy under HIPAA continues to be a compliance challenge. |
| United Kingdom | Devices need to meet UKCA marking rules post- Brexit. The MHRA requires clinical performance data and cybersecurity preparedness for diagnostic software platforms. AI tools are required to comply with the UK Government's Code of Conduct for Data-Driven Health Tech. |
| France | The EU MDR regime and ANSM are responsible for regulation. All devices have to be CE marked. France's digital reimbursement system (For fait Innovation) subsidises the adoption of innovative cardiac testing, but only after they are stringently tested. |
| Germany | MDR requires CE certification, as well as further examination by BfArM. Germany's DiGA scheme provides expedited reimbursement for digital diagnostics that have proven clinical benefit and GDPR data protection compliance. |
| Italy | CE marking is obligatory under EU MDR. AIFA and the Ministry of Health evaluate diagnostic innovations, with increased focus on telecardiology. Public procurement is sluggish, but plans in the country are aiding digitisation in cardiology. |
| South Korea | Governed by the Ministry of Food and Drug Safety (MFDS). The devices need to get KGMP certification. The government encourages AI and digital health technologies, with sandboxes regulating entry for remote diagnosis and wearable-based solutions. |
| Japan | The MHLW and PMDA regulate the industry, requiring approval from SHONIN or Ninsho. Japan requires GVP and QMS compliance with stringent post- industry surveillance. Diagnostics based on AI are subjected to further checks for algorithm transparency and safety. |
| China | Approval by NMPA is necessary, along with CFDA registration. China requires local clinical trials for cardiovascular devices in general. The government is encouraging AI medical device innovation but has strict cybersecurity law adherence and data localisation requirements. |
| Australia-NZ | TGA requires ARTG registration and Essential Principles compliance in Australia. New Zealand follows Med safe requirements. Both nations are encouraging digital diagnostics, with Australia actively considering AI-specific medical device regulations. |
| India | The industry is regulated by CDSCO, with an import licence or manufacturing licence under the Medical Devices Rules, 2017. Cardiac testing was categorised as notified medical devices in 2020. Regulatory clarification on AI-based diagnostics is still unfolding. |
The United States industry for cardiovascular diagnostics is projected to grow at a CAGR of 5.6% during the period from 2025 to 2035. Reimbursement incentives, leadership in AI adoption, and highly developed healthcare infrastructure in the country fuel aggressive industry growth.
Major institutions are proactively embedding AI-augmented ECG, CT, and MRI platforms, backed by the FDA's Digital Health Software Precertification Program. Hospitals are making investments in interoperable diagnostics that are based on HIPAA-compliant data platforms.
Strong R&D ecosystems, high patient volumes, and mandates for preventive screening also promote early diagnosis and high throughput. The FMI analysis found the USA industry to be one of the most innovation-led in the world.
In the United Kingdom, the cardiovascular diagnostics industry is projected to grow at a CAGR of 5.0% during the period 2025 to 2035. Post-Brexit, the shift to UKCA-marked medical devices has added complexity, but national health institutions remain focused on digital cardiology.
The long-term plan of the NHS supports early detection and AI-based diagnostics, with funding schemes encouraging the modernisation of cardiac units. Frameworks for cybersecurity, data governance, and AI transparency align procurement.
FMI believes that public-private partnerships and national strategies for lowering cardiovascular mortality will steadily increase demand, particularly for cloud-based imaging tools and mobile diagnostics.
From 2025 to 2035, projections indicate a CAGR of 5.3% for the cardiovascular diagnostics industry in France. France has accelerated efforts to digitise cardiology departments with robust state-supported healthcare infrastructure and is increasing demand for AI-driven imaging. The ANSM, in accordance with EU MDR, imposes strict assessment requirements and CE certification as an absolute entry requirement.
Reimbursement through Forfait Innovation accelerates adoption of novel tools, provided they demonstrate measurable outcomes. FMI analysis found France’s growing ageing population, regulatory clarity, and emphasis on chronic disease management are strong growth enablers in this sector.
From 2025 to 2035, projections indicate a CAGR of 5.5% for the cardiovascular diagnostics industry in Germany. Germany is at the forefront of digital health integration in the European bloc, driven by the DiGA fast-track program and its established hospital network.
Cardiologists enjoy government-subsidised upgrades to diagnostics, provided they ensure clinical value and comply with GDPR data protection regulations. Demand is particularly high for AI-facilitated echocardiography and handheld diagnostics, which facilitate a more precise diagnosis in the outpatient department.
FMI believes that Germany's regulatory restraint balanced by digital advancement positions it among Europe's most investable cardiovascular diagnostic ecosystems.
Estimates indicate that the cardiovascular diagnostics industry in Italy will grow at a CAGR of 4.8% from 2025 to 2035. Although the Italian industry is quite fragmented, hospital modernisation programs run by national authorities are improving diagnostic penetration. Devices with CE certifications are obligatory, and government grants increasingly favour cloud-based platforms in public cardiology facilities.
FMI research discovered that Italy's increasing burden of chronic diseases and ageing population is driving investments in scalable AI-based solutions, particularly in city-based tertiary care centres. Nevertheless, longer procurement cycles and regional inconsistencies in digital health preparedness could temper growth compared to Western European counterparts.
From 2025 to 2035, projections indicate a CAGR of 5.4% for the cardiovascular diagnostics industry in South Korea. The country's high-density urban agglomerations and age factor have spurred the demand for remote diagnostics and cardiac devices compatible with wearables. MFDS provides regulatory sandboxes for nascent AI development, making way for local players as well as global contestants.
Seoul and Busan hospitals are at the forefront of adopting AI-integrated echocardiograms and intelligent ECG systems. FMI believes that South Korea's government-initiated digital health strategy, 5G networks, and partnerships for medical AI with technology titans present high-impact commercial prospects.
In Japan, the cardiovascular diagnostics industry is projected to grow at a CAGR of 4.6% during 2025 to 2035.
The rapid adoption of new technologies is moderated by cost controls and conservative hospital expenditures, even though Japan maintains excellent healthcare standards. SHONIN certification remains stringent, especially for AI-based diagnostics, and retraining limitations among clinicians limit rapid digitalisation.
Demand for portable and space-saving cardiac testing, though, is increasing in urban and elderly rural populations. FMI research indicated that the use of new technology will speed up after 2027 as payment options become clearer and public-private test programs prove that AI tools can help with heart screening and management.
The cardiovascular diagnostics industry in China is projected to grow at a CAGR of 5.8% during the period from 2025 to 2035. Proactive investments in AI-driven diagnostics and intelligent hospital equipment are underway, as cardiovascular disease remains the nation's leading cause of death.
NMPA approval and domestic clinical validation are required, although the regulatory simplification introduced recently is favourable for local innovation.
Urban hospitals implement cloud-integrated diagnostic equipment, whereas community clinics use more mobile ECG and ultrasound machines.
FMI believes national digital health initiatives, an ageing population, and reforms in public health will push China into the forefront of growth industries globally.
For the Australian-New Zealand industry, the cardiovascular diagnostic industry is set to grow by a CAGR of 5.2% between 2025 and 2035. Both TGA and Medsafe provide stable regulatory regimes, allowing regular industry entry through cutting-edge diagnostics.
The National Health Reform Agreement of Australia drives public hospitals toward embracing AI-augmented cardiac instruments for preventive healthcare and outreach to rural locations.
Remote patient monitoring, especially among underserved populations and indigenous communities, has witnessed government-initiated pilots spreading across states.
FMI analysis indicated that the widespread use of telehealth and the emphasis on portable diagnostic tools will keep boosting growth, but the complicated reimbursement process in New Zealand might slow down early business success.
The projections indicate a CAGR of 6.1% for the cardiovascular diagnostics industry in India from 2025 to 2035. The urbanisation of the country and the increasing incidence of heart disease are driving investments in cost-effective, scalable diagnostic equipment. The CDSCO requires licensing under the Medical Devices Rules, with greater emphasis on software and AI compliance.
Public and private healthcare programs like Ayushman Bharat are increasing diagnostic coverage in tier-2 and tier-3 cities. FMI believes that India's young med-tech ecosystem, government-supported digital health mission, and increasing health insurance coverage make it a high-growth frontier for cardiac testing.
Between 2025 and 2035, Implantable Loop Recorders (ILRs) will be the most profitable product segment, driven by increasing incidence of unexplained syncope, increased need for continuous monitoring of the heart, and incorporation of remote telemetry systems.
The ILR segment is anticipated to record a CAGR of about 6.9% between 2025 and 2035, higher than the general industry growth rate of 5.1%. These subcutaneous models provide diagnostic coverage for years, and their convenience is best suited for those with infrequent arrhythmic bursts and cryptogenic conditions.
Analysis by FMI identified a growing preference for ILRs compared to conventional Holter and event monitoring because they offer better diagnostic yields and compliance with patients.
Simultaneously, AI analytics are now able to send real-time alarmsand monitor patients using cloud technologies in both rural and urban health systems.
Between 2025 and 2035, High-Sensitivity CRP (hs-CRP) Kits will be the most profitable point-of-care testing segment because cardiovascular inflammation becomes a central diagnostic criterion in worldwide risk guidelines.
With continued advancement of smartphone-integrated and microfluidic devices, this application is expected to grow at a CAGR of 6.5% between 2025 and 2035. hs-CRP is increasingly being used on a routine basis in measuring subclinical atherosclerosis and directing statin therapy, especially among individuals who have normal lipid levels but elevated inflammation markers.
FMI believes clinical guidelines promoting aggressive screening and the move toward decentralised diagnostics will spur adoption of hs-CRP kits across emergency environments and outpatient clinics.
Cardiac Catheterisation Labs are poised to be the most profitable end-user segment during 2025 to 2035, given their pivotal role in procedural cardiology and advanced imaging diagnostics.
The Cardiac Catheterisation Lab segment is expected to register a CAGR of around 6.7% during the period from 2025 to 2035. With structural heart interventions, electrophysiology studies, and coronary angiographies increasingly dependent on intravascular diagnostics and haemodynamic monitoring, cath labs are evolving into precision centres for diagnosis as well as treatment.
FMI research has detected more spending on cardiac facilities, higher use of hybrid cath labs, and tighter integration of AI into real-time decision-making, all driving both the volume and complexity of procedures.
In the cardiac testing industry, leading players are competing on a combination of pricing agility, innovation-driven product differentiation, and strategic partnerships.
FMI research found that important companies are putting a lot of money into AI-based diagnostic tools, remote monitoring systems, and wearable ECG technologiesto improve diagnostic accuracy and enhance user accessibility.
Partnerships between telehealth providers and hospital networks are increasing access and adoption rates. At the same time, regional expansion-particularly into Asia and Latin America-is facilitating revenue diversification.
Price-sensitive industries are fuelling demand for portable, cost-effective devices. To remain ahead, top companies are also expanding R&D pipelines and obtaining regulatory clearances to accelerate next-generation cardiac testing.
Industry Share Analysis
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Thermo Fisher Scientific
Danaher Corporation (Beckman Coulter)
BioMérieux
Other Players (Quidel Ortho, Singulex, etc.)
Key Developments in 2024
Roche Diagnostics introduced the cobas® t 711 troponin T assay in early 2024, advancing cardiac risk assessment with better sensitivity. The assay gained FDA clearance, further solidifying Roche's position as a leader in high-sensitivity cardiac biomarkers.
Abbott Laboratories extended its Alinity® hs-troponin-I assay to growing industries, such as India and Brazil, during Q1 2024. The expansion further secured Abbott's position in regions with increasing cardiovascular disease burdens.
Siemens Healthineers acquired Healthineers AG's last shareholding in Rapid Diagnostics in February 2024 to enhance its POC cardiac testing portfolio. The USD 1.2 billion transaction was aimed at speeding up decentralised diagnostics.
Thermo Fisher Scientific collaborated with Cleveland Clinic in April 2024 to establish next-generation cardiac biomarkers. The partnership centres on predictive algorithms for heart failure via Thermo Fisher's BRAHMS™ platform.
QuidelOrtho experienced a regulatory delay when the FDA sent a warning letter in March 2024 regarding manufacturing deficiencies in its Sofia® troponin assay. The firm is trying to resolve compliance issues affecting short-term sales.
BioMérieux obtained CE marking for VIDAS® Kube® automated immunoassay system in January 2024, simplifying cardiac testing in laboratories in Europe. The system incorporates AI-based analytics for quicker results.
The industry is segmented into electrocardiogram (ECG) system, resting ECG systems, cardiopulmonary stress testing systems, holter monitoring devices, event monitoring devices, implantable loop recorder (ILR), others.
The industry is segmented into analyzers, lipoprotein test kits, angiotensin test kits, fibrinogen test kits, serum uric acid test kits, high-sensitivity CRP (hs-CRP) kits.
The industry is segmented into hospitals, ambulatory surgical centers, specialty clinics, cardiac catheterization labs, diagnostic imaging centers.
The industry is studied across North America, Latin America, East Asia, South Asia & Pacific, Europe, Central Asia, Middle East and Africa.
Table 01: Global Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 02: Global Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 03: Global Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 04: Global Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Region
Table 05: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 06: North America Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 07: North America Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 08: North America Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 09: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 10: Latin America Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 11: Latin America Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 12: Latin America Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 13: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 14: Europe Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 15: Europe Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 16: Europe Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 17: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 18: South Asia Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 19: South Asia Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 20: South Asia Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 21: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 22: East Asia Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 23: East Asia Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 24: East Asia Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 25: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 26: Oceania Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 27: Oceania Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 28: Oceania Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Table 29: Middle East and Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 30: Middle East and Africa Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by Product
Table 31: Middle East and Africa Market Volume (Units) Analysis and Forecast 2017 to 2033, by Product
Table 32: Middle East and Africa Market Value (US$ Million) Analysis and Forecast 2017 to 2033, by End User
Figure 01: Global Market Volume (Units), 2017 to 2022
Figure 02: Global Market Volume (Units) & Y-o-Y Growth (%) Analysis, 2023 to 2033
Figure 03: Equipment, Pricing Analysis per unit (US$), in 2022
Figure 04: Equipment, Pricing Forecast per unit (US$), in 2033
Figure 05: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 06: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 07: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022 to 2033
Figure 08: Global Market Value Share (%) Analysis 2023 and 2033, by Product
Figure 09: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Product
Figure 10: Global Market Attractiveness Analysis 2023 to 2033, by Product
Figure 11: Global Market Value Share (%) Analysis 2023 and 2033, by End User
Figure 12: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by End User
Figure 13: Global Market Attractiveness Analysis 2023 to 2033, by End User
Figure 14: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 15: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Region
Figure 16: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 17: North America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 18: North America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 19: North America Market Value Share, by Product (2023 E)
Figure 20: North America Market Value Share, by End User (2023 E)
Figure 21: North America Market Value Share, by Country (2023 E)
Figure 22: North America Market Attractiveness Analysis by Product, 2023 to 2033
Figure 23: North America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 24: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 25: USA Market Value Proportion Analysis, 2022
Figure 26: Global Vs. USA Growth Comparison
Figure 27: USA Market Share Analysis (%) by Product, 2022 & 2033
Figure 28: USA Market Share Analysis (%) by End User, 2022 & 2033
Figure 29: Canada Market Value Proportion Analysis, 2022
Figure 30: Global Vs. Canada. Growth Comparison
Figure 31: Canada Market Share Analysis (%) by Product, 2022 & 2033
Figure 32: Canada Market Share Analysis (%) by End User, 2022 & 2033
Figure 33: Latin America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 34: Latin America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 35: Latin America Market Value Share, by Product (2023 E)
Figure 36: Latin America Market Value Share, by End User (2023 E)
Figure 37: Latin America Market Value Share, by Country (2023 E)
Figure 38: Latin America Market Attractiveness Analysis by Product, 2023 to 2033
Figure 39: Latin America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 40: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 41: Mexico Market Value Proportion Analysis, 2022
Figure 42: Global Vs Mexico Growth Comparison
Figure 43: Mexico Market Share Analysis (%) by Product, 2022 & 2033
Figure 44: Mexico Market Share Analysis (%) by End User, 2022 & 2033
Figure 45: Brazil Market Value Proportion Analysis, 2022
Figure 46: Global Vs. Brazil. Growth Comparison
Figure 47: Brazil Market Share Analysis (%) by Product, 2022 & 2033
Figure 48: Brazil Market Share Analysis (%) by End User, 2022 & 2033
Figure 49: Argentina Market Value Proportion Analysis, 2022
Figure 50: Global Vs Argentina Growth Comparison
Figure 51: Argentina Market Share Analysis (%) by Product, 2022 & 2033
Figure 52: Argentina Market Share Analysis (%) by End User, 2022 & 2033
Figure 53: Europe Market Value (US$ Million) Analysis, 2017 to 2022
Figure 54: Europe Market Value (US$ Million) Forecast, 2023 to 2033
Figure 55: Europe Market Value Share, by Product (2023 E)
Figure 56: Europe Market Value Share, by End User (2023 E)
Figure 57: Europe Market Value Share, by Country (2023 E)
Figure 58: Europe Market Attractiveness Analysis by Product, 2023 to 2033
Figure 59: Europe Market Attractiveness Analysis by End User, 2023 to 2033
Figure 60: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 61: UK Market Value Proportion Analysis, 2022
Figure 62: Global Vs. UK Growth Comparison
Figure 63: UK Market Share Analysis (%) by Product, 2022 & 2033
Figure 64: UK Market Share Analysis (%) by End User, 2022 & 2033
Figure 65: Germany Market Value Proportion Analysis, 2022
Figure 66: Global Vs. Germany Growth Comparison
Figure 67: Germany Market Share Analysis (%) by Product, 2022 & 2033
Figure 68: Germany Market Share Analysis (%) by End User, 2022 & 2033
Figure 69: Italy Market Value Proportion Analysis, 2022
Figure 70: Global Vs. Italy Growth Comparison
Figure 71: Italy Market Share Analysis (%) by Product, 2022 & 2033
Figure 72: Italy Market Share Analysis (%) by End User, 2022 & 2033
Figure 73: France Market Value Proportion Analysis, 2022
Figure 74: Global Vs France Growth Comparison
Figure 75: France Market Share Analysis (%) by Product, 2022 & 2033
Figure 76: France Market Share Analysis (%) by End User, 2022 & 2033
Figure 77: Spain Market Value Proportion Analysis, 2022
Figure 78: Global Vs Spain Growth Comparison
Figure 79: Spain Market Share Analysis (%) by Product, 2022 & 2033
Figure 80: Spain Market Share Analysis (%) by End User, 2022 & 2033
Figure 81: Russia Market Value Proportion Analysis, 2022
Figure 82: Global Vs Russia Growth Comparison
Figure 83: Russia Market Share Analysis (%) by Product, 2022 & 2033
Figure 84: Russia Market Share Analysis (%) by End User, 2022 & 2033
Figure 85: BENELUX Market Value Proportion Analysis, 2022
Figure 86: Global Vs BENELUX Growth Comparison
Figure 87: BENELUX Market Share Analysis (%) by Product, 2022 & 2033
Figure 88: BENELUX Market Share Analysis (%) by End User, 2022 & 2033
Figure 89: East Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 90: East Asia Market Value Share, by Product (2023 E)
Figure 91: East Asia Market Value Share, by End User (2023 E)
Figure 92: East Asia Market Value Share, by Country (2023 E)
Figure 93: East Asia Market Attractiveness Analysis by Product, 2023 to 2033
Figure 94: East Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 95: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 96: China Market Value Proportion Analysis, 2022
Figure 97: Global Vs. China Growth Comparison
Figure 98: China Market Share Analysis (%) by Product, 2022 & 2033
Figure 99: China Market Share Analysis (%) by End User, 2022 & 2033
Figure 100: Japan Market Value Proportion Analysis, 2022
Figure 101: Global Vs. Japan Growth Comparison
Figure 102: Japan Market Share Analysis (%) by Product, 2022 & 2033
Figure 103: Japan Market Share Analysis (%) by End User, 2022 & 2033
Figure 104: South Korea Market Value Proportion Analysis, 2022
Figure 105: Global Vs South Korea Growth Comparison
Figure 106: South Korea Market Share Analysis (%) by Product, 2022 & 2033
Figure 107: South Korea Market Share Analysis (%) by End User, 2022 & 2033
Figure 108: South Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 109: South Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 110: South Asia Market Value Share, by Product (2023 E)
Figure 111: South Asia Market Value Share, by End User (2023 E)
Figure 112: South Asia Market Value Share, by Country (2023 E)
Figure 113: South Asia Market Attractiveness Analysis by Product, 2023 to 2033
Figure 114: South Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 115: South Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 116: India Market Value Proportion Analysis, 2022
Figure 117: Global Vs. India Growth Comparison
Figure 118: India Market Share Analysis (%) by Product, 2022 & 2033
Figure 119: India Market Share Analysis (%) by End User, 2022 & 2033
Figure 120: Indonesia Market Value Proportion Analysis, 2022
Figure 121: Global Vs. Indonesia Growth Comparison
Figure 122: Indonesia Market Share Analysis (%) by Product, 2022 & 2033
Figure 123: Indonesia Market Share Analysis (%) by End User, 2022 & 2033
Figure 124: Malaysia Market Value Proportion Analysis, 2022
Figure 125: Global Vs. Malaysia Growth Comparison
Figure 126: Malaysia Market Share Analysis (%) by Product, 2022 & 2033
Figure 127: Malaysia Market Share Analysis (%) by End User, 2022 & 2033
Figure 128: Thailand Market Value Proportion Analysis, 2022
Figure 129: Global Vs. Thailand Growth Comparison
Figure 130: Thailand Market Share Analysis (%) by Product, 2022 & 2033
Figure 131: Thailand Market Share Analysis (%) by End User, 2022 & 2033
Figure 132: Oceania Market Value (US$ Million) Analysis, 2017 to 2022
Figure 133: Oceania Market Value (US$ Million) Forecast, 2023 to 2033
Figure 134: Oceania Market Value Share, by Product (2023 E)
Figure 135: Oceania Market Value Share, by End User (2023 E)
Figure 136: Oceania Market Value Share, by Country (2023 E)
Figure 137: Oceania Market Attractiveness Analysis by Product, 2023 to 2033
Figure 138: Oceania Market Attractiveness Analysis by End User, 2023 to 2033
Figure 139: Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 140: Australia Market Value Proportion Analysis, 2022
Figure 141: Global Vs. Australia Growth Comparison
Figure 142: Australia Market Share Analysis (%) by Product, 2022 & 2033
Figure 143: Australia Market Share Analysis (%) by End User, 2022 & 2033
Figure 144: New Zealand Market Value Proportion Analysis, 2022
Figure 145: Global Vs New Zealand Growth Comparison
Figure 146: New Zealand Market Share Analysis (%) by Product, 2022 & 2033
Figure 147: New Zealand Market Share Analysis (%) by End User, 2022 & 2033
Figure 148: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022
Figure 149: Middle East & Africa Market Value (US$ Million) Forecast, 2023 to 2033
Figure 150: Middle East & Africa Market Value Share, by Product (2023 E)
Figure 151: Middle East & Africa Market Value Share, by End User (2023 E)
Figure 152: Middle East & Africa Market Value Share, by Country (2023 E)
Figure 153: Middle East & Africa Market Attractiveness Analysis by Product, 2023 to 2033
Figure 154: Middle East & Africa Market Attractiveness Analysis by End User, 2023 to 2033
Figure 155: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033
Figure 156: GCC Countries Market Value Proportion Analysis, 2022
Figure 157: Global Vs GCC Countries Growth Comparison
Figure 158: GCC Countries Market Share Analysis (%) by Product, 2022 & 2033
Figure 159: GCC Countries Market Share Analysis (%) by End User, 2022 & 2033
Figure 160: Türkiye Market Value Proportion Analysis, 2022
Figure 161: Global Vs. Türkiye Growth Comparison
Figure 162: Türkiye Market Share Analysis (%) by Product, 2022 & 2033
Figure 163: Türkiye Market Share Analysis (%) by End User, 2022 & 2033
Figure 164: South Africa Market Value Proportion Analysis, 2022
Figure 165: Global Vs. South Africa Growth Comparison
Figure 166: South Africa Market Share Analysis (%) by Product, 2022 & 2033
Figure 167: South Africa Market Share Analysis (%) by End User, 2022 & 2033
Figure 168: Northern Africa Market Value Proportion Analysis, 2022
Figure 169: Global Vs Northern Africa Growth Comparison
Figure 170: Northern Africa Market Share Analysis (%) by Product, 2022 & 2033
Figure 171: Northern Africa Market Share Analysis (%) by End User, 2022 & 2033
The sales are being fuelled by increased prevalence of cardiovascular disease, improvements in non-invasive technologies, and increased need for early diagnosis.
The industry will grow gradually with rising uptake of AI-driven tools, home diagnostics, and growth in cardiac care infrastructure.
Major players are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., GE Healthcare and Wayra, Siemens Healthineers, Lepu Medical, Midmark Corp, Roche Ltd, Randox Laboratories Ltd., Robonik India, Diasorin, Elabscience Biotechnology, Danaher Corporation (Beckman Coulter), BioMérieux, and Thermo Fisher Scientific.
Implantable Loop Recorders are anticipated to dominate, backed by continuous monitoring and greater diagnostic yield.
It is anticipated to be around USD 10.69 billion by 2035.
Explore Similar Insights
Cardiovascular Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
